================================================================================
--------------------------------------------------------------------------------

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


 Date of Report (Date of earliest event reported): February 22, 2005 
                                                   (February 15, 2005)

                          Altair Nanotechnologies Inc.
              ----------------------------------------------------
             (Exact name of registrant as specified in its charter)

       Canada                       1-12497                  33-1084375     
-----------------------     ----------------------     ---------------------
   (State or other           (Commission File No.)         (IRS Employer
     jurisdiction                                       Identification No.)
  of incorporation)                                   
                                                   
                                 204 Edison Way
                               Reno, Nevada 89502
          ------------------------------------------------------------
          (Address of principal executive offices, including zip code)

       Registrant's telephone number, including area code: (775) 858-3750


                -------------------------------------------------
                   (Former Name, if Changed Since Last Report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously satisfy the filing obligations of the registrant under any of the
following   provisions  (see  General   Instruction  A.2.  below): 

[ ]  Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)
[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)
[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c)

================================================================================
--------------------------------------------------------------------------------

Item 1.01 Entry into a Material Definitive Agreement.

         On February 15, 2005,  Altair  Nanotechnologies  Inc.  (the  "Company")
consummated a public offering of 5,000,000  common shares at a purchase price of
$4.05 per share. The prospectus used in such offering included,  and each of the
purchasers  executed, a Securities Purchase Agreement in the form filed herewith
as Exhibit 10.1 (the "Purchase Agreement").  The Purchase Agreement includes the
terms  of  purchase,   standard  business  and  investor   representations   and
warranties,   conditions  to  closing  and  indemnification   provisions  (which
indemnification  provisions required the Company to indemnify the purchasers for
substantially any claims associated with the transaction).

         In connection with the offering, the Company also entered into a Letter
Agreement dated February 11, 2005 (the "Letter  Agreement") with Maxim Group LLC
("Maxim"), a copy of which incorporated by reference into Item 9.01, under which
it engaged Maxim as its exclusive  financial adviser and placement agent for the
offering. Pursuant to the Letter Agreement, the Company is required to pay Maxim
Group a cash fee equal to 5% of the gross  proceedings  from the offering (which
fee totaled  $1,012,500) and to issue Maxim a warrant to purchase 250,000 common
shares, representing 5% of the number of common shares sold in the offering. The
warrant has an exercise  price equal to $5.265 per share,  representing  130% of
the  offering  price,  a four-year  term and grants  Maxim  one-time  demand and
unlimited  piggy back  registration  rights.  A form of the  warrant is attached
hereto as Exhibit 4.1 We also  agreed to  reimburse  the Maxim Group for actual
costs, not to exceed $25,000 in the aggregate.

         Following  the closing of the  offering,  issuance  of the  warrants to
Maxim and  exercise  of various  outstanding  warrants  and  options to purchase
common  shares,  the Company  has, as of February 16,  2005,  57,993,975  common
shares issued and  outstanding.  In addition,  there are outstanding  options to
purchase  3,014,700  common shares  granted under the under the Company's  stock
option plans and warrants to purchase 1,657,452 common shares.

Item 3.02  Unregistered Sales of Equity Securities

         As  discussed  in Item 1.01  above,  the second  paragraph  of which is
incorporated  herein by  reference,  we  agreed  to issue to Maxim a warrant  to
purchase  250,000  common  shares as of February  15,  2005.  The warrant has an
exercise  price  equal to $5.265 per share,  representing  130% of the  offering
price,  a four-year term and grants Maxim  one-time  demand and unlimited  piggy
back  registration  rights.  A form of the warrant is attached hereto as Exhibit
4.1

         The warrant was offered  and sold in reliance  upon the  exemption  for
sales of  securities  not involving a public  offering,  as set forth in Section
4(2) of the Securities Act, based upon the following:  (a) Maxim represented and
warranted to the Company that it was a registered  broker-dealer and, therefore,
an  "accredited  investor,"  as defined in Rule 501 of  Regulation D promulgated
under the Securities Act and has such background,  education,  and experience in
financial and business matters as to be able to evaluate the merits and risks of
an investment  in the  securities;  (b) there was no public  offering or general
solicitation  with respect to the warrants,  and Maxim represented and warranted
that it was acquiring the  securities for its own account and not with an intent
to distribute  such  securities;  (c) Maxim was provided with a copy of the most
recent Annual Reports on Form 10-K,  Quarterly  Reports on Form 10-Q and Current
Reports on Form 8-K of the Company  and all other  information  requested  by it
with respect to the Company;  (d) Maxim  acknowledged  that all securities being
purchased are  "restricted  securities"  for purposes of the Securities Act, and
agreed to transfer such securities only in a transaction registered with the SEC
under the Securities Act or exempt from  registration  under the Securities Act;
and (e) a  legend  has been  placed  on the  certificates  and  other  documents
representing each such security stating that they are restricted and can only be
transferred if subsequently  registered  under the Securities Act or transferred
in a transaction exempt from registration under the Securities Act.

                                       2


Item 9.01  Financial Statements and Exhibits.

(c) Exhibits.

4.1      Form of Warrant issued to Maxim Group, LLC

10.1     Form of Securities Purchase Agreement

10.2     Letter  Agreement dated February 11, 2005 between the Company and Maxim
         Group LLC  (Incorporated  by reference  from the Current Report on Form
         8-K filed by the Company on February 15, 2005).





                                       3





                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly caused this Current Report on Form 8-K to be signed on
its behalf by the undersigned thereunto duly authorized.


                                           Altair Nanotechnologies Inc.         


     February 22, 2005                     By:       /s/ Edward Dickinson       
     ---------------------------------        ----------------------------------
      Date                                          Edward Dickinson,
                                                    Chief Financial Officer


                                       4